Cancidas (previously Caspofungin MSD) Unjoni Ewropea - Olandiż - EMA (European Medicines Agency)

cancidas (previously caspofungin msd)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimycotica voor systemisch gebruik - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.

Lipoplus 200 mg/ml, emulsie voor infusie Olanda - Olandiż - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

lipoplus 200 mg/ml, emulsie voor infusie

b. braun melsungen ag (melsungen) carl-braun-strasse 1 34212 melsungen (duitsland) - omega-3-olie, geconcentreerd ; sojaolie, gezuiverd ; triglyceriden middellange keten - emulsie voor infusie - ascorbylpalmitaat (e 304) ; glycerol (e 422) ; lecithine (e 322) ; natriumhydroxide (e 524) ; natriumoleaat (e 470a) ; stikstof (head space) (e 941) ; tocoferol, dl-alfa (e 307) ; water, gezuiverd, - fat emulsions

Gabapentine Brillpharma 50 mg/ml drank, suikervrij Olanda - Olandiż - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

gabapentine brillpharma 50 mg/ml drank, suikervrij

brillpharma (ireland) limited iniscarra, main street rathcoole (ierland) - gabapentine - drank - acesulfaam kalium (e 950) ; anijszaadsmaakstof ; carmellose (e 466) ; ethylparahydroxybenzoaat (e 214) ; glyceroltriacetaat (e 1518) ; methylparahydroxybenzoaat (e 218) ; propyleenglycol (e 1520) ; water, gezuiverd

Bylvay Unjoni Ewropea - Olandiż - EMA (European Medicines Agency)

bylvay

albireo - odevixibat - cholestasis, intrahepatic - gal en levertherapie - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or older (see sections 4. 4 en 5.